Finerenone?

Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA) sold under the brand name Kerendia.

- What it’s for: In adults with chronic kidney disease (CKD) due to diabetic kidney disease (type 2 diabetes), finerenone is used to help reduce the risk of sustained eGFR decline, progression to end-stage kidney disease, and certain cardiovascular events. It’s typically added to standard CKD/diabetes therapies (like ACE inhibitors or ARBs).

- How it works: It blocks the mineralocorticoid receptor, which helps reduce inflammation and fibrosis in the kidney and heart.

- How it’s taken: By mouth, once daily. The usual plan is to start at a lower dose (often 10 mg daily) and may be increased to 20 mg daily if kidney function and potassium levels are stable and the patient tolerates it. Your clinician will tailor the dose.

- Key safety and monitoring
- Hyperkalemia (high potassium) is the most important risk. Potassium and kidney function should be checked before starting, within 1–2 weeks after starting or changing the dose, and periodically thereafter.
- Common side effects can include hyperkalemia-related symptoms, dizziness or hypotension, and possible changes in kidney function.
- Contraindications include significant hyperkalemia (high potassium) and pregnancy. Use with caution in those taking other potassium-sparing meds or certain drug interactions.
- Not recommended to use with other mineralocorticoid receptor antagonists at the same time.

- Drug interactions and cautions
- CYP3A4 inhibitors can increase finerenone levels; dosing may need adjustment.
- Avoid or use with caution with medications that raise potassium (e.g., certain aldosterone antagonists, potassium-sparing diuretics) and monitor closely.

If you were looking for something specific, I can tailor this (e.g., a patient-friendly summary, dosing details, monitoring schedule, or trial data). Do you want a quick practical summary for a patient, or deeper details on efficacy and trials (FIDELIO-DKD / FIGARO-DKD)?